Latest news with #ZIMV
Yahoo
24-07-2025
- Business
- Yahoo
ZimVie to Be Taken Private by Archimed in $730 Million Buyout Deal
ZimVie (ZIMV) shares surged intraday Monday after the dental implant company agreed to be acquired a
Yahoo
21-07-2025
- Business
- Yahoo
ZimVie to Be Taken Private by Archimed in $730 Million Buyout Deal
ZimVie (ZIMV) shares surged intraday Monday after the dental implant company agreed to be acquired a Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-06-2025
- Business
- Yahoo
ZimVie Stock Gains Following the Launch of RealGUIDE Software Suite
ZimVie Inc. ZIMV recently launched its RealGUIDE Software Suite and Implant Concierge service in Japan. The RealGUIDE platform enables streamlined workflows and enhanced treatment accuracy, while the Implant Concierge service offers personalized support to clinicians throughout the implant process. Together, these solutions aim to boost clinical efficiency and improve patient outcomes in Japan's rapidly evolving dental landscape. As ZimVie's largest market in the Asia-Pacific region, Japan represents a key growth opportunity. The launch is expected to enhance clinician access to end-to-end, vertically integrated digital workflows, reinforcing ZimVie's strategic focus on innovation and global market penetration. Following the announcement, shares of the company have gained 2.9% and closed at $9.38 on Friday. However, in the year-to-date period, ZIMV's shares have lost 32.7% against the industry's 5.9% growth. The S&P 500 increased 1.5% in the same time frame. The launch of the RealGUIDE Software Suite and Implant Concierge service in Japan positions ZimVie to capture a larger share of a high-potential market by offering advanced digital solutions that align with the global shift toward precision-driven, technology-enabled dentistry. By streamlining workflows and enhancing clinician efficiency, these tools can drive increased adoption of ZimVie implants and related products, fostering customer loyalty and recurring revenue. Over time, this strategic move could strengthen ZimVie's footprint in the APAC region, support margin expansion through high-value services, and contribute to sustainable long-term growth. Meanwhile, ZIMV currently has a market capitalization of $261.2 million. Image Source: Zacks Investment Research ZimVie's launch of the RealGUIDE Software Suite in Japan marks a major advancement in digital implantology, offering dentists a robust, cloud-based platform for precise implant planning, surgical guide design and restorative workflows. As the first fully cloud-integrated system of its kind, RealGUIDE allows clinicians to customize their digital workflows using modular components tailored to diagnostic, surgical, and restorative needs. The integration with ZimVie's Dental Technology Institute and its CAD/CAM milling capabilities ensures a seamless transition from case planning to final restoration, significantly improving treatment accuracy, reducing turnaround times, and enhancing patient care. This end-to-end digital experience is poised to streamline operations for clinics while improving efficiency, precision and cost-effectiveness. Complementing the RealGUIDE platform is the Implant Concierge service, a scalable virtual outsourcing solution that supports clinicians in planning and executing guided surgeries with minimal complexity. Designed for user-friendliness and zero upfront investment, Implant Concierge brings together a team of expert treatment planners and designers to ensure accuracy at every step. It integrates directly with dental labs to offer a smooth, fully coordinated experience from planning to final placement, especially beneficial for high-volume practices. Per a report by MarketsandMarkets, the global digital dentistry market, valued at $6.5 billion in 2022, is forecasted to grow at a robust CAGR of 10.9%, reaching $12.2 billion by 2028. The digital dentistry market is rising due to the growing demand for faster, more accurate, and patient-friendly dental procedures. Advancements in 3D imaging, CAD/CAM systems, and cloud-based software are enabling dentists to deliver personalized treatments with greater precision and efficiency. ZIMV carries a Zacks Rank #3 (Hold) at present. Some better-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report ZimVie Inc. (ZIMV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
ZimVie Inc (ZIMV) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
Total Revenue: $112 million for Q1 2025. Adjusted EBITDA: Over $17 million, with a margin of 15.7%. Adjusted EBITDA Margin Improvement: Over 500 basis points improvement compared to Q1 2024. Adjusted Cost of Products Sold: 33.6% of sales, a decrease of 360 basis points from the prior year. Net Sales Decline: 5.2% decrease in reported rates; 4.1% decline in constant currency. US Net Sales: $65.8 million, a decline of 2.8% compared to the prior year. Outside US Net Sales: $46.2 million, a decrease of 8.5% on a reported basis. Adjusted R&D Expenses: $5.4 million, or 4.8% of sales. Adjusted SG&A Expenses: $58.7 million, a decrease of 2.7% from the prior year. Adjusted Earnings Per Share: $0.27, a 238% increase from the prior year period. Cash Balance: $67 million at the end of Q1 2025. Gross Debt: Approximately $220 million, with net debt of approximately $153 million. Biomaterials Growth: Just over 1% growth during the quarter. Digital Dentistry Growth: High single digits growth, with implant concierge service growing 11% year-over-year. Guidance for Full Year 2025 Revenue: $445 million to $460 million. Guidance for Full Year 2025 Adjusted EBITDA: $65 million to $70 million. Guidance for Full Year 2025 EPS: $0.80 to $0.95 per share. Warning! GuruFocus has detected 4 Warning Signs with ZIMV. Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ZimVie Inc (NASDAQ:ZIMV) achieved a significant improvement in adjusted EBITDA margin, reaching 15.7%, which is over 500 basis points higher than the first quarter of 2024. The company successfully reduced the adjusted total cost of products sold by over 350 basis points, enhancing profitability. ZimVie Inc (NASDAQ:ZIMV) launched a new immediate molar implant system, which exceeded internal growth expectations and is expected to drive growth for the remainder of the year. The digital dentistry business, excluding scanner sales, grew by high single digits, with the implant concierge service growing 11% year-over-year. The acquisition of a distributor partner in Costa Rica is expected to provide immediate benefits to the company's margin profile by leveraging local infrastructure and customer relationships. Net sales for the first quarter decreased by 5.2% in reported rates and 4.1% in constant currency, indicating a decline in top-line performance. The US market saw a 2.8% decline in net sales, driven by lower implant sales and the impact of one less selling day. International sales decreased by 8.5% on a reported basis, with significant headwinds from the expiration of a transition manufacturing agreement and lower China sales. The dental implant sales declined in low single digits due to continued macroeconomic pressures. The company faces potential tariff-related costs estimated at $3 million per year, primarily due to EU-USA tariff rates, which could impact profitability. Q: Can you provide more details on the uptick in implant units sold in April? Is this due to higher utilization, same-store sales, or new accounts? A: Vafa Jamali, President and CEO, explained that while Q1 was similar to Q4, March showed improvement, and April demonstrated resilience. The increase is primarily due to improved same-store sales. The new immediate molar implant launch is performing better than expected, contributing to the growth in implant units. Q: How is pricing trending in the dental implant market, and can you offset tariff impacts with price increases? A: Vafa Jamali noted that the premium implant market is less price-competitive compared to value lines. While there are competitive pricing situations, especially with larger deals, the company aims to package deals beneficial for both customers and ZimVie. They plan to be selective with price increases, relying on accurate market segmentation to avoid competitive disadvantages. Q: What accounts for the greater decline in international sales compared to the US? A: Richard Heppenstall, CFO, highlighted several headwinds affecting international sales, including FX impacts, termination of a low-margin manufacturing agreement, fewer selling days, and reduced focus on China. When normalized for these factors, international sales declined modestly by 1.6%. Q: Can you discuss your position in the Japanese market and the potential impact of the Implant Concierge launch? A: Vafa Jamali stated that ZimVie's market position in Japan is similar to the US, with good pricing for premium implants. The Implant Concierge service could significantly boost business by improving workflow, which is a barrier to adoption. Richard Heppenstall added that Japan showed mid-single-digit growth in Q1, and the new service is expected to accelerate momentum. Q: How confident are you in your supply chain and manufacturing capabilities amid economic and logistical challenges? A: Vafa Jamali expressed strong confidence in ZimVie's manufacturing capabilities, citing flexibility with sites in Florida and Valencia. The company has moved distribution nodes to avoid US tariffs and has largely exited China, reducing risk. They have in-sourced manufacturing from China to Valencia, improving margins and avoiding tariffs. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
